No Data
HUTCHMED Expands Brokerage Partnerships in London
HUTCHMED's Share Option Scheme Update and Stock Issuance
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
Orient: Initiates a "Buy" rating for Hutchmed (China) (00013) with a Target Price of 33.24 HKD.
Orient predicts that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion dollars for the years 2024-2026 respectively.
No Data
